Press coverage about Eyegate Pharmaceuticals (NASDAQ:EYEG) has trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Eyegate Pharmaceuticals earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave press coverage about the specialty pharmaceutical company an impact score of 44.1573878497126 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- EyeGate’s Phase 3 EGP-437 study fails to show non-inferiority (massdevice.com)
- Global Anterior Uveitis Drug Market 2018 – Aciont Inc., Aldeyra Therapeutics, Inc., EyeGate Pharmaceuticals, Inc., KPI … (thefairreporter.com)
- Most Recent Update on Price Move: EyeGate Pharmaceuticals, Inc. (EYEG) closed Monday at $0.48 with -14.29 … (talktraders.com)
- Trading updates about Stock: EyeGate Pharmaceuticals, Inc. (EYEG), Costamare Inc. (CMRE) (talktraders.com)
- EyeGate randomizes first patients in punctate epitheliopathies study (healio.com)
Shares of Eyegate Pharmaceuticals stock traded down $0.04 during mid-day trading on Friday, reaching $0.39. 554,389 shares of the stock were exchanged, compared to its average volume of 227,063. The stock has a market capitalization of $18.66 million, a P/E ratio of -0.38 and a beta of 3.46. Eyegate Pharmaceuticals has a fifty-two week low of $0.29 and a fifty-two week high of $1.38.
Eyegate Pharmaceuticals (NASDAQ:EYEG) last announced its earnings results on Friday, August 3rd. The specialty pharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.07. The firm had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.81 million. equities analysts predict that Eyegate Pharmaceuticals will post -0.34 EPS for the current year.
Separately, HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of Eyegate Pharmaceuticals in a research report on Monday, June 25th.
About Eyegate Pharmaceuticals
EyeGate Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system.
Further Reading: Determine Your Level of Risk Tolerance
Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.